Pharmaceuticals Anonymous

Friday, February 6, 2009

How the Bailout Benefits Big Pharma - and YOU Will Pay For It


At about the 1:20 mark, Mr. Kucinich mentions Pfizer's $68 Billion buyout of Wyeth - for which YOU will pay. The New York times article link is here.

Thursday, February 5, 2009

Rest in Peace, Lux

Lux Interior, founder and lead singer of the punkabilly group the Cramps, has died.
Here he performs for patients inside Napa State Mental Hospital.

http://en.wikipedia.org/wiki/The_Cramps

Tuesday, February 3, 2009

Alzheimer's and B3/Niacin


Vitamin B3/Niacin as Alzheimer's therapy:
"Memory loss is the signature feature of Alzheimer's disease, and therapies that prevent or delay its onset are urgently needed. Effective preventive strategies likely offer the greatest and most widespread benefits. Histone deacetylase (HDAC) inhibitors increase histone acetylation and enhance memory and synaptic plasticity. We evaluated the efficacy of nicotinamide, a competitive inhibitor of the sirtuins or class III NAD+-dependent HDACs in 3xTg-AD mice, and found that it restored cognitive deficits associated with pathology. Nicotinamide selectively reduces a specific phospho-species of tau (Thr231) that is associated with microtubule depolymerization, in a manner similar to inhibition of SirT1. Nicotinamide also dramatically increased acetylated -tubulin, a primary substrate of SirT2, and MAP2c, both of which are linked to increased microtubule stability. Reduced phosphoThr231-tau was related to a reduction of monoubiquitin-conjugated tau, suggesting that this posttranslationally modified form of tau may be rapidly degraded. Overexpression of a Thr231-phospho-mimic tau in vitro increased clearance and decreased accumulation of tau compared with wild-type tau. These preclinical findings suggest that oral nicotinamide may represent a safe treatment for AD and other tauopathies, and that phosphorylation of tau at Thr231 may regulate tau stability."
Link
More here: Link
A link has been established between Alzheimer's and calcium - a substance we take like candy in antacids. Link
What is the counterbalance for calcium? Magnesium. What makes magnesium work better? Niacin....

Monday, February 2, 2009

Stop Bill C-51 Campaign Revived



It's baaaaack...Canada's vitamin-banning Bill C-51 has been reworked as Bill C-6.


Stop Bill C-51 -- CODEX ALIMENTARIUS -- Call to Action from Anonymai on Vimeo.

Who Owns Nature? Pharma, Of Course!

Monsantoland Pictures, Images and Photos

Further extracts from ETC Group's recently released report, "Who Owns Nature?" These are from the section about the pesticde industry. For the full report:
http://www.etcgroup.org/en/materials/publications.html?pub_id=707

According to the report, the world's six largest agrochemical manufacturers, who control nearly 75% of the global pesticide market, are also seed industry giants.

It's worth breaking this down by company.

Bayer: the world's biggest agrochemical company is also the world's seventh biggest seed company.

Syngenta: the world's second largest agrochemical company is also the world's third largest seed company.

Monsanto: the world's biggest seed company is the world's fifth largest agrochemical company.

And DuPont: the world's second biggest seed company is also the world's sixth largest agrochemical company.

All these companies are gene giants.

Weed killers (herbicides) account for about one-third of the global pesticide market, and around 80% of GM seeds involve herbicide-resistance.

The worldwide market for agrochemicals grew last year by nearly 10%.
------
Who Owns Nature?
Report from ETC Group

[Extracts only]

Agrochemical Industry

World's Top 10 Pesticide Firms

Company - Agrochemical Sales 2007 (US$ millions) - % Market Share

1.Bayer (Germany) - $7,458m - 19%
2.Syngenta (Switzerland) - $7,285m - 19%
3.BASF (Germany) - $4,297m - 11%
4.Dow AgroSciences (USA) - $3,779m - 10%
5.Monsanto (USA) - $3,599m - 9%
6.DuPont (USA) - $2,369m - 6%
7.Makhteshim Agan (Israel) - $1,895m - 5%
8.Nufarm (Australia) - $1,470m - 4%
9.Sumitomo Chemical (Japan) - $1,209m - 3%
10.Arysta Lifescience (Japan) - $1,035m - 3%
Total $34,396m - 89%
Source: Agrow World Crop Protection News, August 2008

The top 10 companies control 89% of the global agrochemical market.

The worldwide market for agrochemicals was US$38.6 billion in 2007 - up 8.4% over the previous year. The top 6 companies accounted for $28.8 billion, or 75% of the total market.


Link

Canada - take action on genetic modification here

Thursday, January 29, 2009

Rolling Stone article plagiarizes Furious Seasons

Furious Seasons blog owner and investigative journalist Philip Dawdy writes,

"This news brought to you courtesy of the Zyprexa documents, which Rolling Stone apparently used in reporting its recent lengthy story on Zyprexa, but didn't attribute to the appropriate source. They are just referred to as "internal documents" in the article, completely ignoring the very substantial risks some folks went to to make those documents public.
Yes, the RS article is now online and I've read it. I want to re-read it before deciding whether to take out a plinging gun or a .50 caliber machine gun.
Despite giving the reporter loads of help for his story and going unmentioned and unattributed, one thing I'll tell you right now is that the article is entitled "Bitter Pill." Ironically enough, last year I wrote an article for Willamette Week on how negative anti-depressant clinical trials data had been suppressed for decades. The article's title was "Bitter Pill." While article titles are up for grabs, it just charms me beyond belief that RS chose, coincidentally I'm sure, a title I'd already used. Classic."

RS article is here

A fine shout-out to Dawdy's giant-killing work at Furious Seasons is
here. - Why doesn't Rolling Stone hire Philip Dawdy?

Wednesday, January 28, 2009

Is Caffeine Driving You Crazy?



Drinking copious cups of coffee isn’t just bad for your health, it’s also more likely to drive you crazy, or at least crazy enough to hear voices. According to a study published in the academic journal “Personal and Individual Differences,” people who consumed the equivalent of more than seven cups of coffee per day (330 mg) were more likely to have hallucinations than those who consumed less than one cup (10 mg).


The articles link, link claim that they have not quite worked out why this is so. However, caffeine, an alkaloid, was known as a psychoactive to the Cherokee in America before written history,
and caffeine psychosis was identified in Western medical literature at least as early as 1936. Go here to see Blogger StoneSoupStation's great collection of coffee craziness links.

For decades, orthomolecular physician and psychiatrist Dr. Abram Hoffer has recommended elimination of caffeine from the diets of his schizophrenic patients - and they get well:
'The majority of scientists and psychiatrists subscribe to the dopamine excess theory of schizophrenia--that too much dopamine is largely responsible for the symptoms of psychosis. However, since 1952, Dr. Abram Hoffer, the founding father of orthomolecular medicine, has researched, published, and expanded upon the adrenochrome theory of schizophrenia. (1,2) He and his colleagues, Drs. Osmond and Smythies, came to this theory by studying and researching the effects of substances such as mescaline, lysergic acid diethylamide (LSD), and amphetamines--all of which can cause a clinical syndrome in normal individuals that would be clinically indistinguishable from schizophrenia.

Hoffer noticed that mescaline had a similar chemical structure to that of adrenaline, and since both can be converted to indoles in the body, the potential schizophrenic toxin might be an indole derivative of adrenaline with similar neurochemical properties to that of mescaline or LSD. He eventually deduced that the schizophrenic toxin was an oxidized derivative of adrenaline known as adrenochrome. Since the early 1950s, Hoffer's adrenochrome theory has been validated due to the following findings:

* that adrenochrome and its close relatives--dopaminochrome (from dopamine) and noradrenochrome (from noradrenaline)--are present in the human brain, (3-5)

* that these compounds probably induce a combination of neurotoxic and mind-mood-altering effect, and (3-5)

* that reducing adrenochrome and its close relatives is therapeutic for the treatment of schizophrenia. (6)

The majority of schizophrenic patients (about 90%) who receive mainstream treatments remain unwell and nonfunctional for the rest of their lives despite receiving the most advanced drugs and social services currently available. (7) Estimates of first episode schizophrenics are a little more optimistic, reporting that of five recently diagnosed patients, one will recover sufficiently to live an almost normal life without medication or with very low doses of medication. (8) The economic costs of schizophrenia to society are enormous, amounting to approximately two million dollars for each schizophrenic patient over a 40-year course of the illness. (9)

In a recent publication examining the economic burden of schizophrenia in Canada, the direct and non-direct heath care costs associated with this disease were estimated to be 2.02 billion Canadian dollars in 2004. (10) In addition, when these figures were added to the high unemployment rate with additional productivity, morbidity, and mortality losses, the estimate reached 4.83 billion Canadian dollars, for a total cost estimate of 6.85 billion Canadian dollars in 2004. The authors of this report arrived at the following conclusion: "Despite significant improvements in the past decade in pharmacotherapy, programs, and services available for patients with schizophrenia, the economic burden of schizophrenia in Canada remains high."

The purpose of the report is to highlight the problems with the standard medical treatment of schizophrenia and to demonstrate that the addition of orthomolecular medicine provides patients with the best opportunity of living a reasonable quality of life. Common orthomolecular treatments are reviewed, including summaries of relevant clinical studies and prescribing information. Four patient cases are described to show the reader the potential benefits of this approach, as well as the difficulties with this approach when certain essential treatment components are lacking.'
Source

You can read a short article on Hoffer's methodology here, and
see Dr. Hoffer's book on nutrition and mental health, PUTTING IT ALL TOGETHER, here. Hoffer's work remains the gold standard in the field and he is a hero and savior to many.